{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:51:32Z","timestamp":1761648692594,"version":"3.44.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T00:00:00Z","timestamp":1604793600000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.annder.2019.09.010","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T09:15:27Z","timestamp":1572254127000},"page":"740-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Toxidermies"],"prefix":"10.1016","volume":"146","author":[{"given":"J.-L.","family":"Bourrain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2019.09.010_bib0405","first-page":"2S163","article-title":"Iatrog\u00e9nie. Diagnostic et pr\u00e9vention. Toxidermies m\u00e9dicamenteuses","volume":"129","author":"Roujeau","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.09.010_bib0410","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0190-9622(85)70207-1","article-title":"Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases","volume":"13","author":"Ruiz-Maldonado","year":"1985","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0415","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0151-9638(07)89201-5","article-title":"Prise en charge globale des toxidermies","volume":"134","author":"Barbaud","year":"2007","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.09.010_bib0420","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International Consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2019.09.010_bib0425","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.2165\/00002018-200730110-00003","article-title":"Drug-induced skin, nail and hair disorders","volume":"30","author":"Valleyrie-Allanore","year":"2007","journal-title":"Drug Safe"},{"key":"10.1016\/j.annder.2019.09.010_bib0430","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/01.all.0000173785.81024.33","article-title":"Epidemiology of hypersensitivity drug reactions","volume":"5","author":"Gomes","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0435","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1365-2125.2010.03774.x","article-title":"Epidemiology and risk factors for drug allergy","volume":"71","author":"Thon","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.annder.2019.09.010_bib0440","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.amjmed.2013.09.008","article-title":"Recognition and first-line treatment of anaphylaxis","volume":"127","author":"Lieberman","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.annder.2019.09.010_bib0445","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.annfar.2010.12.012","article-title":"Moyens diagnostiques des r\u00e9actions imm\u00e9diates","volume":"30","author":"Laroche","year":"2011","journal-title":"Ann Fr Anesth Reanim"},{"key":"10.1016\/j.annder.2019.09.010_bib0450","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1034\/j.1398-9995.2003.00280.x","article-title":"(ENDA). Diagnosis of immediate allergic reactions to beta-lactam antibiotics","volume":"58","author":"Torres","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2019.09.010_bib0455","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1398-9995.2011.02557.x","article-title":"Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI\/ENDA and GA2LEN\/HANNA","volume":"66","author":"Kowalski","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2019.09.010_bib0460","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000342424","article-title":"Clinical management of patients with a history of urticaria\/angioedema induced by multiple NSAIDs: an expert panel review","volume":"160","author":"Asero","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0465","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000356702","article-title":"Multiple nonsteroidal anti-inflammatory drug-induced cutaneous disease: what differentiates patients with and without underlying chronic spontaneous urticaria?","volume":"163","author":"Asero","year":"2014","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0470","first-page":"7","article-title":"Overview of hereditary \u201cangioedema\u201d caused by C1-inhibitor deficiency: assessment and clinical management","volume":"45","author":"Bork","year":"2013","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0475","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.revmed.2012.12.017","article-title":"(CREAK). Management of angiotensin-converting enzyme inhibitor-related angioedema: recommendations from the French National Center for Angioedema","volume":"34","author":"Nosbaum","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.annder.2019.09.010_bib0480","series-title":"Toxidermies\u00a0: aspects clinqiues et scores. Progr\u00e8s en dermato-allergologie","first-page":"157","author":"Avenel-Audran","year":"2013"},{"key":"10.1016\/j.annder.2019.09.010_bib0485","series-title":"Tests cutan\u00e9s dans les toxidermies graves. Progr\u00e8s en dermato-allergologie","first-page":"191","author":"Barbaud","year":"2013"},{"key":"10.1016\/j.annder.2019.09.010_bib0490","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clindermatol.2013.05.027","article-title":"Photodermatoses, including phototoxic and photoallergic reactions (internal and external)","volume":"32","author":"Kutlubay","year":"2014","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0495","series-title":"Phototoxicit\u00e9, photoallergie\u00a0: diagnostic et prise en charge. Progr\u00e8s en dermato-allergologie","first-page":"135","author":"Bourrain","year":"2008"},{"key":"10.1016\/j.annder.2019.09.010_bib0500","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.medmal.2011.09.016","article-title":"Phototoxicity and photocarcinogenesis associated with voriconazole","volume":"41","author":"Epaulard","year":"2011","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.annder.2019.09.010_bib0505","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(12)70413-8","article-title":"Cutaneous toxicities of RAF inhibitors","volume":"14","author":"Anforth","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annder.2019.09.010_bib0510","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.0105-1873.2004.00445.x","article-title":"Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?","volume":"51","author":"Hausermann","year":"2004","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.annder.2019.09.010_bib0515","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1684\/ejd.2010.0980","article-title":"A three-year-analysis of fixed drug eruptions in hospital settings in France","volume":"20","author":"Brahimi","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0520","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1684\/ejd.2013.2055","article-title":"\u201cCutaneous adverse drug reactions\u201d are not always drug-induced","volume":"23","author":"Raison-Peyron","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0525","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1684\/ejd.2010.0932","article-title":"Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts","volume":"20","author":"Speeckaert","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0530","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1440-0960.2011.00845.x","article-title":"Acute generalised exanthematous pustulosis","volume":"53","author":"Fernando","year":"2012","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0535","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1034\/j.1600-0560.2001.028003113.x","article-title":"Acute generalized exanthematous pustulosis (AGEP) \u2013 a clinical reaction pattern","volume":"28","author":"Sidoroff","year":"2001","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.annder.2019.09.010_bib0540","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0545","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D397D8T291","article-title":"Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome","volume":"8","author":"Ghislain","year":"2002","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2019.09.010_bib0550","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: part II. Management and therapeutics","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0555","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jaad.2013.01.033","article-title":"DRESS syndrome: part I. Clinical perspectives","volume":"68","author":"Husain","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0560","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/bjd.12501","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0565","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0570","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1346-8138.2010.01176.x","article-title":"News aspects of drug-induced hypersensitivity syndrome","volume":"38","author":"Tohyama","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0575","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.annder.2019.09.010_bib0580","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/jid.2012.510","article-title":"Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"133","author":"Sekula","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0585","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0590","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2019.09.010_bib0595","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.mjafi.2013.01.007","article-title":"Severe cutaneous adverse drug reactions","volume":"69","author":"Verma","year":"2013","journal-title":"Med J Armed Forces India"},{"key":"10.1016\/j.annder.2019.09.010_bib0600","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.annder.2011.01.010","article-title":"Linear IgA bullous dermatosis: a review","volume":"138","author":"Ingen-Housz-Oro","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.09.010_bib0605","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000353584","article-title":"Linear IgA bullous disease presenting as toxic epidermal necrolysis: a case report and review of the literature","volume":"227","author":"Kakar","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.annder.2019.09.010_bib0610","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1346-8138.2005.tb00839.x","article-title":"Drug-induced linear IgA bullous dermatosis","volume":"32","author":"Onodera","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0615","first-page":"270","article-title":"Studies of the multiple drug allergy syndrome","volume":"83","author":"Sullivan","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0620","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/ACI.0b013e3283630c36","article-title":"Multiple drug hypersensitivity syndrome","volume":"13","author":"Chiriac","year":"2013","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0625","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1346-8138.2010.01142.x","article-title":"Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity","volume":"38","author":"Pichler","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0630","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.revmed.2014.10.004","volume":"36","author":"Lebrun-Vignes","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.annder.2019.09.010_bib0635","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.jaci.2010.11.048","article-title":"Immune pathomechanism of drug hypersensitivity reactions","volume":"127","author":"Pichler","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0640","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.12304","article-title":"Contributions of pharmacogenetics and transcriptomics to the understanding of the hypersensitivity drug reactions","volume":"69","author":"Fernandez","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2019.09.010_bib0645","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bjd.12253","article-title":"Allergy workup of severe cutaneous adverse drug reactions: a light at the end of the tunnel?","volume":"168","author":"Schnyder","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0650","doi-asserted-by":"crossref","first-page":"46ra62","DOI":"10.1126\/scitranslmed.3001116","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiform antiviral T cell response","volume":"2","author":"Picard","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.annder.2019.09.010_bib0655","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"Toxidermies group of the French Society of Dermatology. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0660","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jbspin.2013.05.002","article-title":"DRESS syndrome","volume":"81","author":"Descamps","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.annder.2019.09.010_bib0665","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/565320","article-title":"HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review","author":"Cheng","year":"2014","journal-title":"J Immunol Res"},{"key":"10.1016\/j.annder.2019.09.010_bib0670","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.annder.2019.09.010_bib0675","series-title":"La chronologie dans les toxidermies - L\u2019art pour l\u2019art ou utilit\u00e9 clinique\u00a0? Progr\u00e8s en dermato-allergologie - Lyon 2013","first-page":"199","author":"Bircher","year":"2013"},{"key":"10.1016\/j.annder.2019.09.010_bib0680","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2011.08.006","article-title":"Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals","volume":"56","author":"Cacoub","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0685","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.amjcard.2010.11.002","article-title":"Management of clopidrogel hypersensitivity without drug interruption","volume":"107","author":"Campbell","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.annder.2019.09.010_bib0690","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jaci.2012.02.029","article-title":"Nonimmediate drug allergy: diagnostic benefit of skin testing and practical approach","volume":"129","author":"Schnyder","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0695","first-page":"442","article-title":"Reducing the risk of anaphylaxis during anesthesia: 2011\u00a0Updated Guidelines for Clinical Practice","volume":"21","author":"Mertes","year":"2011","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0700","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.2174\/138161208786369731","article-title":"Provocation tests in diagnosing drug hypersensitivity","volume":"14","author":"Bousquet","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.annder.2019.09.010_bib0705","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1398-9995.2004.00678.x","article-title":"Diagnosis of nonimmediate reactions to beta-lactam antibiotics","volume":"59","author":"Romano","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2019.09.010_bib0710","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1034\/j.1398-9995.2003.00280.x","article-title":"Diagnosis of immediate allergic reactions to beta-lactam antibiotics","volume":"58","author":"Torres","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2019.09.010_bib0715","first-page":"213","article-title":"In vitro methods for diagnosing nonimmediate hypersensitivity reactions to drugs","volume":"23","author":"Mayorga","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0720","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/ACI.0b013e328216f4d4","article-title":"Recent advances in the diagnosis of drug allergy","volume":"7","author":"Romano","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0725","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/cea.12145","article-title":"In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test","volume":"43","author":"Porebski","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.annder.2019.09.010_bib0730","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2332\/allergolint.08-CR-0035","article-title":"Acute generalized exanthematous pustulosis (AGEP) triggered by a spider bite","volume":"58","author":"Makris","year":"2009","journal-title":"Allergol Int"},{"key":"10.1016\/j.annder.2019.09.010_bib0735","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1346-8138.2010.01155.x","article-title":"Hypersensitivity syndrome due to trichloroethylene exposure: a severe generalized skin reaction resembling drug-induced hypersensitivity syndrome","volume":"38","author":"Watanabe","year":"2011","journal-title":"J Dermatol"},{"key":"10.1016\/j.annder.2019.09.010_bib0740","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.annder.2012.01.025","article-title":"Bullous drug eruption with Nigella sativa oil","volume":"139","author":"Gelot","year":"2012","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.09.010_bib0745","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1398-9995.2010.02441.x","article-title":"General considerations on rapid desensitization for drug hypersensitivity \u2013 a consensus statement","volume":"65","author":"Cernadas","year":"2010","journal-title":"Allergy"},{"key":"10.1016\/j.annder.2019.09.010_bib0750","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00262-012-1273-x","article-title":"Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization","volume":"61","author":"Castells","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annder.2019.09.010_bib0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.10.003","article-title":"Allergy to sulfonamides","volume":"131","author":"Schnyder","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.annder.2019.09.010_bib0760","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.iac.2014.04.003","article-title":"Adverse events to nontargeted and targeted chemotherapeutic agents. Drug hypersensitivity","volume":"34","author":"Baldo","year":"2014","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.annder.2019.09.010_bib0765","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000327767","article-title":"Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment","volume":"4","author":"Farr","year":"2011","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.annder.2019.09.010_bib0770","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1.3\u00a0galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2019.09.010_bib0775","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5070\/D32G73V82N","article-title":"Letter: neutrophilic eccrine hidroadenitis with atypical findings","volume":"17","author":"Grillo","year":"2011","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2019.09.010_bib0780","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annder.2012.12.012","article-title":"Pigmentary disorders induced by anticancer agents. Part I: chemotherapy","volume":"140","author":"Sibaud","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.09.010_bib0785","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0151-9638(08)70093-0","article-title":"Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitor","volume":"135","author":"Deslandres","year":"2008","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2019.09.010_bib0790","first-page":"1395","article-title":"Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm","volume":"20","author":"Reguiai","year":"2012","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annder.2019.09.010_bib0795","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.iac.2014.04.008","article-title":"Hypersensitivity reactions to biologic agents","volume":"34","author":"Vultaggio","year":"2014","journal-title":"Immunol Allergy Clin N Am"},{"key":"10.1016\/j.annder.2019.09.010_bib0400","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biological agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819303242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963819303242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:07:39Z","timestamp":1758971259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963819303242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0151963819303242"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2019.09.010","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxidermies","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2019.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}